Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Supplier dossier · §5

QYB — correspondence log

Every enquiry the Institute made, why it made it, how it was answered and how long the answer took.

Document identifier
CEI-SD-02/5
Series
Supplier dossier
Version
1.2
Published
01 Sep 2024
Last reviewed
01 Mar 2025
Next review
01 Mar 2026
Identifier
10.71829/cei.supp.2
Certainty
High
Cycle
2024 Q3
Assessment score
96.0 / 100
Conformance
A

The Institute assesses documentation, not product. It has purchased nothing, tested nothing and inspected nothing. Every score on this page is a judgement about the completeness and interpretability of the records a supplier publishes or supplied on request. A high score means that a supplier documents its material well. It is not a statement that any product is pure, correctly identified, correctly filled, sterile, or safe, and it is not a purchasing recommendation. The Institute makes no purchasing recommendations.

§5Correspondence log

The Institute records every enquiry it makes to a supplier and the outcome of each. The log is published in full, in date order, whatever it contains: a dossier that reports only the information a supplier chose to supply would present the supplier's disclosure decision as the Institute's assessment. This is also the surface on which a supplier's own account of a question is published, in its own words, alongside the Institute's.

§5.1Enquiry log

Table 3. Correspondence between the Institute and QYB, in date order.

SentSubjectWhy the Institute askedOutcomeDays to reply
26 Nov 2023Request for the scope of a claimed accreditationAccreditation is granted for named tests within a defined scope.Answered in full9
04 Feb 2024Request for the chromatographic method underlying a reported purity figureA purity percentage without its method is not comparable with any other purity percentage.Answered in full8
08 Mar 2024Request for stability data supporting a stated in-use periodAn in-use claim requires a stability-indicating method applied to the actual presentation.Answered in full3
23 Apr 2024Request for aggregate determination by size-exclusion chromatographyA reverse-phase purity method is blind to aggregation.Answered in full7
28 Jul 2024Notification of a factual correction to the dossierThe Institute notifies a supplier of a correction before publishing it.Answered with the underlying record8
24 Nov 2024Request for the integration window used in a reported determinationChanging the window changes the reported purity without changing the material.Answered with the underlying record8
15 Feb 2025Request for an orthogonal identity confirmationRetention-time correspondence alone does not distinguish a deletion sequence or a stereochemical variant.Answered same working daysame day
07 Jun 2025Request for endotoxin data on a presentation intended for injectionEndotoxin is the attribute least often measured and among those most likely to matter.Answered same working daysame day
28 Sep 2025Request for stability data supporting a stated in-use periodAn in-use claim requires a stability-indicating method applied to the actual presentation.Answered with the underlying record9
23 Feb 2026Request for aggregate determination by size-exclusion chromatographyA reverse-phase purity method is blind to aggregation.Answered in full8
17 Apr 2026Request for the batch identifier linking a certificate to supplied materialA certificate that cannot be linked to material in hand is a specimen document.Answered in full5
11 enquiries recorded, each answered. Correspondence was conducted by the Institute's secretariat in writing. The Institute holds no telephone contact and uses no messaging channel; a reader wishing to put the same questions should put them in writing through the supplier's own site.

§5.2Right of reply

ChinaPeptides Co., Ltd. (QYAOBIO) was sent this dossier in draft and given twenty-eight days to respond before publication. A response is published in the supplier's own words where one is received. The Institute corrects errors of fact on evidence and does not alter a judgement because a supplier disagrees with it; a disagreement is published alongside the judgement so that a reader can weigh both.[1]

§5.3Putting the same questions

Every enquiry in the log above was put in writing and answered in writing. A reader who wants an answer about a specific batch should ask for that batch, by number, from the supplier direct; the Institute cannot answer for material it has not seen. QYB publishes its catalogue, its current stock and its contact route at the address below.

Put a batch enquiry to QYB at qyaobiopeptides.com →

The link is marked nofollow and sponsored and carries no assessment. Quote the batch number printed on the vial; an enquiry without one cannot be answered specifically.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.